Definitive Contract HHSN272201500004C
Award Date
5/6/15
Potential Completion Date
4/30/19
Potential Value
$6.2M
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
BCN Biosciences LLC
Ultimate Awardee
Not listed
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Pasadena, CA 91107, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
7
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Meabco Inc. for the "ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2" project. The contract has a ceiling value of $6,434,348.32 and a period of performance ending on April 30, 2025. The contract stems from a Broad Agency Announcement (BAA) seeking proposals to develop safe and effective medical countermeasures to...
This is a $4,499,688.00 cost-plus-fixed-fee definitive contract with Innovation Pathways, LLC to support the pharmacological development of IPW-5371 fumarate as a radiation medical countermeasure for the treatment of delayed radiation lung injury. The contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and is not a set-aside. The contract was sourced from a Broad Agency Announcement (BAA) seeking proposals...
This is a federal contract award to the University of Maryland, Baltimore (UMB) from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The contract, valued at $63,079,974.98, is for providing product development support services related to medical countermeasures against radiological threats. The contract was awarded on September 30, 2005 and has a completion date of November 21, 2013. There is no set-aside designation for this award,...
This is a definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health within the Department of Health and Human Services, to Duke University for the development of radiation biodosimetry devices and medical countermeasures. The contract has a ceiling value of $6,012,086 and a period of performance from March 1, 2024 to February 28, 2027. The contract was awarded under a Broad Agency Announcement that sought proposals...
This federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID) to Ceramedix Holding, LLC, a small disadvantaged business, is for the development of an anticeramide treatment as a novel medical countermeasure for the acute effects of radiation exposure. The $4,723,612.00 cost-plus-fixed-fee contract has a performance period through June 30, 2026. The contract involves two major subcontractors: the Sloan-Kettering Institute for Cancer Research, a non-profit...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $3,079,369.00 cost-plus-fixed-fee contract to Bolder Biotechnology Inc., a self-certified small disadvantaged business, for the advanced development of BBT-059 as a radiation medical countermeasure. This definitive contract, awarded on July 1, 2023, supports Bolder Biotechnology's efforts to develop a safe and effective treatment that can be administered up to 48 hours after radiation exposure to mitigate associated...
This is a cost-plus-fixed-fee delivery order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to SRI International, a non-profit research and development institute. The contract is for $6,245,298.00 to provide radiation/nuclear medical countermeasure (MCM) product development support services, specifically animal model development and initial efficacy testing of candidate MCMs. This task order is part...
This is a $3,097,981.00 definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to The Medical College of Wisconsin, Inc. (MCW) for the "Mitigation of Multi-Organ Delayed Effects of Acute Radiation Exposure (DEARE) with ACE-Inhibitor Lisinopril". The contract has no set-aside designation. MCW has issued two subcontracts under this award to New York University School of Medicine, worth an unspecified amount, to support the research and...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,624,116.99 definitive contract to the University of Wisconsin System to provide centralized dosimetry guidance and monitoring of radiation sources and irradiation protocols across institutions funded by NIAID's Radiation Nuclear Countermeasures Program (RNCP) portfolio. The contract, which has no set-aside designation, was awarded on June 1, 2020 and runs through May 31, 2025. The contractor will be responsible for...
This is a delivery order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services (HHS), to the non-profit research organization SRI International. The contract, which has a ceiling value of $10,540,438.89, provides administrative and technical support services for the development of radiation/nuclear medical countermeasures (MCM). This task order is part of a larger, indefinite delivery vehicle (IDV)...